174 related articles for article (PubMed ID: 33478296)
1. The iron chelator deferoxamine decreases myeloma cell survival.
Yang F; Wu Z; Dai D; Zhang L; Zhang X; Zhang X; Xu Y
J Int Med Res; 2021 Jan; 49(1):300060520987396. PubMed ID: 33478296
[TBL] [Abstract][Full Text] [Related]
2. Iron chelators induce autophagic cell death in multiple myeloma cells.
Pullarkat V; Meng Z; Donohue C; Yamamoto VN; Tomassetti S; Bhatia R; Krishnan A; Forman SJ; Synold TW
Leuk Res; 2014 Aug; 38(8):988-96. PubMed ID: 24998390
[TBL] [Abstract][Full Text] [Related]
3. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
[TBL] [Abstract][Full Text] [Related]
4. The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.
Wang L; Li X; Mu Y; Lu C; Tang S; Lu K; Qiu X; Wei A; Cheng Y; Wei W
J Trace Elem Med Biol; 2019 Dec; 56():131-138. PubMed ID: 31466045
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.
Porter JB; Abeysinghe RD; Marshall L; Hider RC; Singh S
Blood; 1996 Jul; 88(2):705-13. PubMed ID: 8695819
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation with deferoxamine: comparing the results of a critical pathway to a national survey.
DeSwarte-Wallace J; Groncy PK; Finklestein JZ
J Pediatr Hematol Oncol; 1999; 21(2):136-41. PubMed ID: 10206460
[TBL] [Abstract][Full Text] [Related]
8. Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron.
Haney SL; Varney ML; Safranek HR; Chhonker YS; G-Dayanandan N; Talmon G; Murry DJ; Wiemer AJ; Wright DL; Holstein SA
Leuk Res; 2019 Feb; 77():17-27. PubMed ID: 30612055
[TBL] [Abstract][Full Text] [Related]
9. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.
Ikeda Y; Ozono I; Tajima S; Imao M; Horinouchi Y; Izawa-Ishizawa Y; Kihira Y; Miyamoto L; Ishizawa K; Tsuchiya K; Tamaki T
PLoS One; 2014; 9(2):e89355. PubMed ID: 24586712
[TBL] [Abstract][Full Text] [Related]
11. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
13. p38 and ERK MAP kinase mediates iron chelator-induced apoptosis and -suppressed differentiation of immortalized and malignant human oral keratinocytes.
Lee SK; Jang HJ; Lee HJ; Lee J; Jeon BH; Jun CD; Lee SK; Kim EC
Life Sci; 2006 Sep; 79(15):1419-27. PubMed ID: 16697418
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of deferoxamine on lead-induced cardiotoxicity in rats.
Gazeri A; Aminzadeh A
Toxicol Ind Health; 2020 Oct; 36(10):800-806. PubMed ID: 32812511
[TBL] [Abstract][Full Text] [Related]
15. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice.
Zhang WJ; Wei H; Frei B
Exp Biol Med (Maywood); 2010 May; 235(5):633-41. PubMed ID: 20463304
[TBL] [Abstract][Full Text] [Related]
16. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
[TBL] [Abstract][Full Text] [Related]
17. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
18. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
19. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
[TBL] [Abstract][Full Text] [Related]
20. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
Abdelrazik N
Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
